Abstract
The current coronavirus disease 2019 (COVID-19) outbreak has created a huge demand for rapid and high-volume vaccine manufacturing. Several new platform technologies and traditional manufacturing approaches are being used to meet this demand. Among them, the mRNA vaccine platform technology holds great promise for obtaining an emergency use authorization to facilitate immunization against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which causes the respiratory illness COVID-19. However, this is a new technology, which means that there is significant uncertainty about possible production at a large scale and speed. Vaccines of mRNA work by providing our cells with the genetic code to make viral proteins. Once proteins that do not cause any disease are produced, the body triggers an immune response against the virus, allowing them to develop immunity. mRNA can be used to make any protein theoretically. Still, it is much easier to produce than the proteins themselves or the inactivated and attenuated versions of viruses commonly used in vaccines, which makes this technique attractive, says mRNA specialist Norbert Pardi, at the University of Pennsylvania.